• Majed A Alghamdi, Rajab A Alzahrani, Hashem H Alhashemi, Arwa A Obaid, Ali G Alghamdi, Mohammed A Aldokhi, Amal M Alghamdi, Abdulaziz A Alghamdi, Ahmed S Qanat, Wasil A Jastaniah, and Suliman M Alghamdi.
• Department of Internal Medicine, Faculty of Medicine, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia. E-mail. malghamdi1984@gmail.com.
• Saudi Med J. 2020 Mar 1; 41 (3): 261-266.

ObjectivesTo assess the quality and quantity of Saudi publications in oncology over a 10-year period.MethodsA systematic PubMed search was conducted between January 2008 and December 2017 to retrieve all Saudi oncology publications. Data about the articles was collected. The level of evidence (LOE) was independently assessed by 2 authors. Two 5-year periods (2008-2012 and 2013-2017) were compared using the relevant parameters. Clinicaltrials.gov was also searched for all oncology trials registered in Saudi Arabia.ResultsA total of 839 publications met our inclusion criteria. The most common type of research was case series, totaling 32% of all publications. Clinical trials formed less than 2% of the total. The LOE was I, II, III, and IV in 0.3%, 2.1%, 58.4%, and 39.3% of the included publications, respectively. The LOE was the same in the 2 periods. There were more publications in international journals (p=0.004), more international collaborations (p=0.001), and higher journal impact factors (p=0.037) in 2013-2017 than in 2008-2012. Only 76 registered clinical trials were found in the Clinicaltrials.gov registry.ConclusionDespite an increase in the number of Saudi publications in the field of oncology over time, the LOE did not change. There were, however, some improvements in the international collaboration and journal impact factor, as well as an increase in the number of studies published in international journals. These observations call for a national strategy to improve oncology research in Saudi Arabia.

17 keywords...

hide…